-
平臺(tái)編號(hào)：bio-69782
-
細(xì)胞信息： Kasumi-3
-
規(guī)格：1×10?cells/T25培養(yǎng)瓶
-
用途：STR
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類(lèi)或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
人骨髓白血病細(xì)胞Kasumi-3
細(xì)胞名稱(chēng)：人骨髓白血病細(xì)胞Kasumi-3
產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細(xì)胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運(yùn)輸方式：常溫保溫運(yùn)輸；干冰運(yùn)輸
安全等級(jí)：1
用途限制：僅供科研3類(lèi)
培養(yǎng)體系：DMEM(HYCLONE SH30022.01)+10%FBS+1%三抗
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡(jiǎn)介：人骨髓白血病細(xì)胞Kasumi-3取自57歲男性供體
注釋：Part of:MD Anderson Cell Lines Project.
Population:Japanese.
Doubling time:55-60 hours(PubMed=8613429);~3-4 days(DSMZ).
Omics:Protein expression by reverse-phase protein arrays.
Omics:SNP array analysis.
Omics:Transcriptome analysis.
Derived from sampling site:Bone marrow myeloblasts.
基因突變
HLA信息
/
STR信息
Amelogenin X
CSF1PO 12
D3S1358 14,15
D5S818 13
D7S820 11,12
D8S1179 14,16
D13S317 11,12
D16S539 12
D18S51 12,13
D21S11 29
FGA 22,23
Penta D 8,11
Penta E 15,20
TH01 6
TPOX 8,11
vWA 16,17
參考文獻(xiàn)
PubMed=8613429;DOI=10.1111/j.1349-7006.1996.tb00216.x
Asou H.,Suzukawa K.,Kita K.,Nakase K.,Ueda H.,Morishita K.,Kamada N.
Establishment of an undifferentiated leukemia cell line(Kasumi-3)with t(3;7)(q27;q22)and activation of the EVI1 gene.
Jpn.J.Cancer Res.87:269-274(1996)
DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In)ISBN 9780122219702;pp.1-733;Academic Press;London(2001)
PubMed=14504097;DOI=10.1182ood-2003-02-0418
Taketani T.,Taki T.,Sugita K.,Furuichi Y.,Ishii E.,Hanada R.,Tsuchida M.,Sugita K.,Ida K.,Hayashi Y.
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Blood 103:1085-1088(2004)
PubMed=23955599;DOI=10.1038.2731
Kon A.,Shih L.-Y.,Minamino M.,Sanada M.,Shiraishi Y.,Nagata Y.,Yoshida K.,Okuno Y.,Bando M.,Nakato R.,Ishikawa S.,Sato-Otsubo A.,Nagae G.,Nishimoto A.,Haferlach C.,Nowak D.,Sato Y.,Alpermann T.,Nagasaki M.,Shimamura T.,Tanaka H.,Chiba K.,Yamamoto R.,Yamaguchi T.,Otsu M.,Obara N.,Sakata-Yanagimoto M.,Nakamaki T.,Ishiyama K.,Nolte F.,Hofmann W.K.,Miyawaki S.,Chiba S.,Mori H.,Nakauchi H.,Koeffler H.P.,Aburatani H.,Haferlach T.,Shirahige K.,Miyano S.,Ogawa S.
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.
Nat.Genet.45:1232-1237(2013)
PubMed=28196595;DOI=10.1016/j.ccell.2017.01.005
Li J.,Zhao W.,Akbani R.,Liu W.,Ju Z.,Ling S.,Vellano C.P.,Roebuck P.,Yu Q.,Eterovic A.K.,Byers L.A.,Davies M.A.,Deng W.,Gopal Y.N.V.,Chen G.,von Euw E.M.,Slamon D.J.,Conklin D.,Heymach J.V.,Gazdar A.F.,Minna J.D.,Myers J.N.,Lu Y.,Mills G.B.,Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)
PubMed=32180206;DOI=10.1007/s13577-020-00347-5
Kasai F.,Asou H.,Ozawa M.,Kobayashi K.,Kuramitsu H.,Satoh M.,Kohara A.,Kaneko Y.,Kawamura M.
Kasumi leukemia cell lines:characterization of tumor genomes with ethnic origin and scales of genomic alterations.
Hum.Cell 33:0-0(2020)
細(xì)胞操作說(shuō)明下載：細(xì)胞操作說(shuō)明
產(chǎn)品規(guī)格：T25培養(yǎng)瓶x1；1.5ml凍存管x2
細(xì)胞數(shù)量：1x10^6；1x10^6
保存溫度：37℃；-198℃
運(yùn)輸方式：常溫保溫運(yùn)輸；干冰運(yùn)輸
安全等級(jí)：1
用途限制：僅供科研3類(lèi)
培養(yǎng)體系：DMEM(HYCLONE SH30022.01)+10%FBS+1%三抗
培養(yǎng)溫度：37℃
二氧化碳濃度：5%
簡(jiǎn)介：人骨髓白血病細(xì)胞Kasumi-3取自57歲男性供體
注釋：Part of:MD Anderson Cell Lines Project.
Population:Japanese.
Doubling time:55-60 hours(PubMed=8613429);~3-4 days(DSMZ).
Omics:Protein expression by reverse-phase protein arrays.
Omics:SNP array analysis.
Omics:Transcriptome analysis.
Derived from sampling site:Bone marrow myeloblasts.
基因突變
HLA信息
/
STR信息
Amelogenin X
CSF1PO 12
D3S1358 14,15
D5S818 13
D7S820 11,12
D8S1179 14,16
D13S317 11,12
D16S539 12
D18S51 12,13
D21S11 29
FGA 22,23
Penta D 8,11
Penta E 15,20
TH01 6
TPOX 8,11
vWA 16,17
參考文獻(xiàn)
PubMed=8613429;DOI=10.1111/j.1349-7006.1996.tb00216.x
Asou H.,Suzukawa K.,Kita K.,Nakase K.,Ueda H.,Morishita K.,Kamada N.
Establishment of an undifferentiated leukemia cell line(Kasumi-3)with t(3;7)(q27;q22)and activation of the EVI1 gene.
Jpn.J.Cancer Res.87:269-274(1996)
DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In)ISBN 9780122219702;pp.1-733;Academic Press;London(2001)
PubMed=14504097;DOI=10.1182ood-2003-02-0418
Taketani T.,Taki T.,Sugita K.,Furuichi Y.,Ishii E.,Hanada R.,Tsuchida M.,Sugita K.,Ida K.,Hayashi Y.
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Blood 103:1085-1088(2004)
PubMed=23955599;DOI=10.1038.2731
Kon A.,Shih L.-Y.,Minamino M.,Sanada M.,Shiraishi Y.,Nagata Y.,Yoshida K.,Okuno Y.,Bando M.,Nakato R.,Ishikawa S.,Sato-Otsubo A.,Nagae G.,Nishimoto A.,Haferlach C.,Nowak D.,Sato Y.,Alpermann T.,Nagasaki M.,Shimamura T.,Tanaka H.,Chiba K.,Yamamoto R.,Yamaguchi T.,Otsu M.,Obara N.,Sakata-Yanagimoto M.,Nakamaki T.,Ishiyama K.,Nolte F.,Hofmann W.K.,Miyawaki S.,Chiba S.,Mori H.,Nakauchi H.,Koeffler H.P.,Aburatani H.,Haferlach T.,Shirahige K.,Miyano S.,Ogawa S.
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.
Nat.Genet.45:1232-1237(2013)
PubMed=28196595;DOI=10.1016/j.ccell.2017.01.005
Li J.,Zhao W.,Akbani R.,Liu W.,Ju Z.,Ling S.,Vellano C.P.,Roebuck P.,Yu Q.,Eterovic A.K.,Byers L.A.,Davies M.A.,Deng W.,Gopal Y.N.V.,Chen G.,von Euw E.M.,Slamon D.J.,Conklin D.,Heymach J.V.,Gazdar A.F.,Minna J.D.,Myers J.N.,Lu Y.,Mills G.B.,Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)
PubMed=32180206;DOI=10.1007/s13577-020-00347-5
Kasai F.,Asou H.,Ozawa M.,Kobayashi K.,Kuramitsu H.,Satoh M.,Kohara A.,Kaneko Y.,Kawamura M.
Kasumi leukemia cell lines:characterization of tumor genomes with ethnic origin and scales of genomic alterations.
Hum.Cell 33:0-0(2020)
細(xì)胞操作說(shuō)明下載：細(xì)胞操作說(shuō)明
